JPH0453471A - Bone-enriched food, feed and medicine - Google Patents
Bone-enriched food, feed and medicineInfo
- Publication number
- JPH0453471A JPH0453471A JP2165085A JP16508590A JPH0453471A JP H0453471 A JPH0453471 A JP H0453471A JP 2165085 A JP2165085 A JP 2165085A JP 16508590 A JP16508590 A JP 16508590A JP H0453471 A JPH0453471 A JP H0453471A
- Authority
- JP
- Japan
- Prior art keywords
- egg yolk
- feed
- soluble fraction
- fraction
- egg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 210000000988 bone and bone Anatomy 0.000 title abstract description 9
- 235000014106 fortified food Nutrition 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 108091005804 Peptidases Proteins 0.000 claims abstract description 15
- 102000035195 Peptidases Human genes 0.000 claims abstract description 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 10
- 239000011574 phosphorus Substances 0.000 claims abstract description 10
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 10
- 102000002322 Egg Proteins Human genes 0.000 claims description 63
- 108010000912 Egg Proteins Proteins 0.000 claims description 63
- 210000002969 egg yolk Anatomy 0.000 claims description 28
- 235000013345 egg yolk Nutrition 0.000 claims description 27
- 238000005728 strengthening Methods 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 238000000354 decomposition reaction Methods 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 238000011033 desalting Methods 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 16
- 239000011575 calcium Substances 0.000 abstract description 16
- 229910052791 calcium Inorganic materials 0.000 abstract description 16
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000243 solution Substances 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 238000000909 electrodialysis Methods 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 241000272525 Anas platyrhynchos Species 0.000 abstract description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 2
- 208000012659 Joint disease Diseases 0.000 abstract description 2
- 239000003674 animal food additive Substances 0.000 abstract description 2
- 235000008429 bread Nutrition 0.000 abstract description 2
- 239000001110 calcium chloride Substances 0.000 abstract description 2
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000001132 Osteoporosis Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001223 reverse osmosis Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229960001322 trypsin Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229940036811 bone meal Drugs 0.000 description 2
- 239000002374 bone meal Substances 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011034 membrane dialysis Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000288147 Meleagris gallopavo Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940037448 calcitonin preparations Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 210000001534 vitelline membrane Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【発明の詳細な説明】
童粟上■肌■公国
本発明は、卵黄を脱脂して得られる卵黄蛋白及び／また
はペプチドよりなる水可溶性画分または、蛋白分解酵素
分解物の水可溶性画分を含有せしめてなる骨強化食品、
飼料または医薬に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention uses a water-soluble fraction consisting of egg yolk proteins and/or peptides obtained by defatting egg yolks, or a water-soluble fraction of proteolytic enzyme decomposition products. Bone-strengthening food containing
Concerning feed or medicine.
さらに、本発明は、水可溶性画分から卵黄由来のリンを
含む塩類を除去し、このようなリンが除去された画分と
、適当なカルシウム塩とを併用せしめてなる骨強化食品
、飼料または医薬に関する。Furthermore, the present invention provides bone-strengthening foods, feeds, or pharmaceuticals made by removing salts containing phosphorus derived from egg yolk from the water-soluble fraction, and combining the fraction from which phosphorus has been removed with an appropriate calcium salt. Regarding.
従来艮杏
近年、高齢化に伴い、骨粗鬆症、骨折および腰痛などの
各種骨疾患の患者が増加している。これらはカルシウム
の摂取不足、カルシウム吸収能の低下、活性化ビタミン
０１分泌の不足およびホルモンのアンバランスなどが原
因であるといわれていが主体であるので、カルシウム吸
収の面で吸収さ現在力ルソウムの補給を目的として炭酸
カルシウム、乳酸カルシウム、およびリン酸カルシウム
などのカルシウム塩や牛骨粉、卯殻および魚骨粉などの
天然カルシウム剤が使われている。In recent years, with the aging of the population, the number of patients suffering from various bone diseases such as osteoporosis, bone fractures, and lower back pain has increased. These are said to be mainly caused by insufficient calcium intake, decreased calcium absorption ability, insufficient secretion of activated vitamin 01, and hormonal imbalance. Calcium salts such as calcium carbonate, calcium lactate, and calcium phosphate, and natural calcium preparations such as beef bone meal, shellfish, and fish bone meal are used for supplementation purposes.
現在、骨粗■症や、骨強化のだめの医薬としては、ビタ
ミン１α（Ｏ）ｌ）Ｄ３およびカルシトニン製剤などが
ある。しかし、これらは医薬そのものであって、食品素
材を使う安全でしかも長期的にマイルドな条件で摂取し
て、骨強化をする物質については知られていない。Currently, medicines for osteoporosis and bone strengthening include vitamin 1α(O)l)D3 and calcitonin preparations. However, these are medicines themselves, and there is no knowledge of substances that use food ingredients and can be taken safely over a long period of time under mild conditions to strengthen bones.
また、卵黄中のミネラルは、リン酸塩が多く、カルシウ
ム、リンの比率がカルシウムの吸収性において好ましく
ない。In addition, the minerals in egg yolk are rich in phosphates, and the ratio of calcium to phosphorus is unfavorable in terms of calcium absorption.
゛しよ゛としている
卵黄は天然素材としてずくれているが、卵黄をそのまま
食品または医薬として摂取したとしても卵黄ペプチドお
よび蛋白を多量に摂取利用することができない。また、
卵黄中のミネラルは、リンれにくい。Egg yolk, which is firm and swollen, is a natural material, but even if egg yolk is taken as a food or medicine, it is not possible to ingest and utilize large amounts of egg yolk peptides and proteins. Also,
Minerals in egg yolks are difficult to remove.
本発明は、このような従来の卵黄由来のペプチド及び蛋
白の利用ならびにカルシウムの吸収の改善を目的として
なされたものである。すなわち、本発明は、卵黄ペプチ
ド及び蛍白を多量に吸収することができ、骨を強化する
作用があり、カルシウムの吸収を改善することのできる
骨強化食品及び医薬を提供することを課題とする。The present invention was made with the aim of utilizing such conventional egg yolk-derived peptides and proteins and improving calcium absorption. That is, an object of the present invention is to provide a bone-strengthening food and medicine that can absorb a large amount of egg yolk peptide and fluorescent white, have a bone-strengthening effect, and can improve calcium absorption. .
ｔａ ｔ”るための
本発明者らは、卵黄蛋白及びペプチドを吸収することが
でき、またカルシウムの吸収をも促進することのできる
食品、飼料及び医薬を、卵黄から得ることについて検討
を行った。その結果、卵黄を脱脂して得られる水可溶性
画分あるいは、蛋白分解酵素により加水分解して得られ
る水可溶性画分あるいはこれらの両分から逆浸透（ＲＯ
）膜または電気透析（ＥＯ）等により卵黄由来の塩を除
いたペプチドおよび蛋白混合物は吸収され易く、骨を強
化する作用があり、さらにこれらに吸収性の良いカルシ
ウム剤を添加することによりカルシウム吸収を一段と促
進することができることを見出した。The present inventors have investigated the possibility of obtaining foods, feeds, and medicines from egg yolk that can absorb egg yolk proteins and peptides and can also promote calcium absorption. As a result, the water-soluble fraction obtained by defatting the egg yolk, the water-soluble fraction obtained by hydrolyzing it with proteolytic enzymes, or both of these fractions is subjected to reverse osmosis (RO).
) A mixture of peptides and proteins from which the salts derived from egg yolk are removed by membrane or electrodialysis (EO) etc. is easily absorbed and has the effect of strengthening bones, and by adding a highly absorbable calcium agent to these, calcium absorption can be improved. We have found that it is possible to further promote
そして、これらの知見に基づいて骨を強化する作用を有
する食品および医薬を得るに至ったものである。Based on these findings, we have now obtained foods and medicines that have the effect of strengthening bones.
すなわち、本発明は、
（１） 卵黄を脱脂し、得られる卵黄蛋白及びペプチ
ドよりなる水可溶性画分を含有せしめてなる骨強化食品
、飼料または医薬。That is, the present invention provides: (1) A bone-strengthening food, feed, or medicine containing a water-soluble fraction consisting of egg yolk proteins and peptides obtained by defatting egg yolk.
（２）卵黄を脱脂し、得られる卵黄蛋白及びペプチドの
水可溶性画分を蛋白分解酵素で酵素分解し、得られる分
子量４００００〜２０００の蛋白分解酵素分解物よりな
る水可溶性画分を含有せしめてなる骨強化食品、飼料ま
たは医薬。(2) Defatting the egg yolk, enzymatically decomposing the resulting water-soluble fraction of egg yolk proteins and peptides with a protease, and containing the resulting water-soluble fraction consisting of a proteolytic enzyme decomposition product with a molecular weight of 40,000 to 2,000. bone-strengthening food, feed or medicine.
（３）卵黄蛋白及びペプチドよりなる水可溶性画分また
は蛋白分解酵素分解物よりなる水可溶性画分をさらに脱
塩しこれを含有せしめてなる請求項（１）または（２）
記載の骨強化食品、飼料または医薬。(3) Claim (1) or (2) wherein the water-soluble fraction consisting of egg yolk protein and peptide or the water-soluble fraction consisting of a proteolytic enzyme decomposition product is further desalted and contained.
Bone-strengthening food, feed or medicine as described.
（４）卵黄蛋白及びペプチドよりなる水可溶性画分また
は、蛋白分解酵素分解物よりなる水可溶性画分を脱塩し
て卵黄由来のリンを含む塩を除き、これを適当なカルシ
ウム塩とともに含有せしめてなる請求項（１）〜（３）
のいずれかに記載の骨強化食品、飼料または医薬。(4) Desalting the water-soluble fraction consisting of egg yolk proteins and peptides or the water-soluble fraction consisting of proteolytic enzyme decomposition products to remove salts containing egg yolk-derived phosphorus, and containing this together with an appropriate calcium salt. Claims (1) to (3)
Bone-strengthening food, feed or medicine according to any of the above.
本発明における原料の卵は、鶏卵、アヒル卯、ウズラ卯
、七面鳥などがあげられる。Examples of the raw material eggs in the present invention include chicken eggs, duck eggs, quail rabbits, and turkey eggs.
本発明における脱脂は、卵黄に脱脂溶媒を加えて数時間
撹拌し、卵黄中の脂溶性成分を除去することにより行わ
れ１、脱脂溶媒には、食品素材として安全に使用できる
ｎ−へキサン、エタノールあるいはその混合物を例示す
ることができる。このようにして脂溶性成分を除去した
残渣は水溶性であり、本発明ではこの画分をそのまま、
または脱塩濃縮したりあるいは乾燥したりして使用する
。Defatting in the present invention is performed by adding a defatting solvent to egg yolk and stirring for several hours to remove fat-soluble components in the egg yolk.1 The defatting solvent includes n-hexane, which can be safely used as a food material, An example is ethanol or a mixture thereof. The residue obtained by removing fat-soluble components in this way is water-soluble, and in the present invention, this fraction is used as it is.
Or use after desalting, concentrating, or drying.
脱脂後、蛋白分解酵素による酵素分解を行う場合には、
この溶液あるいは懸濁液に蛋白分解酵素を添加して酵素
分解する。蛋白分解酵素には、ぺプシン、トリプシン、
キモトリプシン等を使用することができる。酵素反応は
、溶液または懸濁液を使用する酵素の至適ｐＨ１至適温
度になるように調整し、酵素を添加し、数１０分〜数時
間放置乃至撹拌を行うことによってなされる。このよう
にすると、分子量４００００〜２０００程度の蛋白分解
酵素分解物を得ることができる。この蛋白分解酵素分解
物は卵黄の蛋白またはペプチドよりなるものである。After delipidation, if enzymatic decomposition with proteolytic enzymes is performed,
A protease is added to this solution or suspension for enzymatic decomposition. Proteolytic enzymes include pepsin, trypsin,
Chymotrypsin etc. can be used. The enzyme reaction is carried out by adjusting the solution or suspension to the optimum pH and temperature of the enzyme used, adding the enzyme, and leaving or stirring for several tens of minutes to several hours. In this way, a proteolytic enzyme decomposition product having a molecular weight of about 40,000 to 2,000 can be obtained. This protease-digested product consists of egg yolk proteins or peptides.
本発明における水可溶性画分は、カルシウム吸収に好ま
しくないリンを多量に含むので、これを脱塩して吸収性
のよいカルシウム塩に置換することが望ましい。このた
めには、まず、水溶性画分を脱塩する。脱塩は、逆浸透
（ＲＯ）膜または電気透析（ＥＤ）で行うとよく、この
ようにすると卵黄由来のリンが除去され、各両分が濃縮
される。さらに、これらと吸収性のよいカルシウム塩と
を置換するときは、塩化カルシウム、炭酸カルシウム、
乳酸カルシウム、卵殻あるいは牛乳由来のカルシウム等
の吸収性のよいカルシウム塩あるいはその含有物を添加
するとよい。Since the water-soluble fraction in the present invention contains a large amount of phosphorus, which is unfavorable for calcium absorption, it is desirable to desalt it and replace it with a calcium salt that has good absorbability. For this purpose, first, the water-soluble fraction is desalted. Desalination may be performed using a reverse osmosis (RO) membrane or electrodialysis (ED), which removes phosphorus from the egg yolk and concentrates both components. Furthermore, when replacing these with calcium salts with good absorption, calcium chloride, calcium carbonate,
It is preferable to add highly absorbable calcium salts such as calcium lactate, calcium derived from eggshells or milk, or substances containing calcium salts thereof.
本発明の食品、飼料あるいは医薬は、これらの水可溶性
画分、あるいはこれらの両分の脱塩画分さらにこの脱塩
画分に吸収性のよいカルシウム塩を添加してなるもの等
を含有するものである。The food, feed, or medicine of the present invention contains these water-soluble fractions, or a desalted fraction of both of these fractions, and a product obtained by adding a highly absorbable calcium salt to this desalted fraction. It is something.
食品の例を挙げると、飲料、ゼリー、錠剤、パン、麺、
スープ、ソーセージ等があり、飼料には、飼料添加物、
その他の飼料が、さらに医薬としては経口的に投与でき
る錠剤、顆粒側、液剤等があげられる。これらの医薬は
経口的に投与され、骨粗鬆症（オステオボローゼ）の予
防あるいは治療に用いられる。投与量は成人、約３００
０〜７０００■／１日を数回に分けて投与することが望
ましい。また、前記画分は元来、卵の成分であって、ラ
ットによる動物試験でも急性毒性は認められなかった。Examples of foods include beverages, jelly, tablets, bread, noodles,
There are soups, sausages, etc., and the feed includes feed additives,
Other feeds and medicines include tablets, granules, liquid preparations, etc. that can be administered orally. These drugs are administered orally and are used to prevent or treat osteoporosis. Dosage for adults: approx. 300
It is desirable to administer 0 to 7,000 μ/day in several doses. Furthermore, the fraction is originally a component of eggs, and no acute toxicity was observed in animal tests using rats.
次に、本発明の卵黄ペプチド及び蛋白の製造法を実施例
をあげて説明する。Next, the method for producing egg yolk peptide and protein of the present invention will be explained with reference to Examples.
実施例１
卵黄蛋白質（ＥＹＰ−Ｎ）の調製性
新鮮鶏卵２０個を平割によって割卵し、卵黄・卵白分離
機を用いて、卵黄を分離した。分離した卵黄を生理食塩
水で洗滌し、残存する卵白を除去後、卵黄膜をピンセッ
トで破り、卵黄を得た。卵黄を合せてよく混合したあと
、ｎ−へキサン：エタノール溶液（９：１．ｖ／ｖ）
５ ｊ２を加えて、５時間撹拌し、遠心分離によって脂
溶性成分を除去した。Example 1 Preparation of egg yolk protein (EYP-N) Twenty fresh chicken eggs were split by flat splitting, and the yolks were separated using an egg yolk/egg white separator. The separated egg yolk was washed with physiological saline to remove the remaining albumen, and the vitelline membrane was broken with tweezers to obtain the egg yolk. Combine the egg yolks and mix well, then add n-hexane:ethanol solution (9:1.v/v)
5j2 was added, stirred for 5 hours, and fat-soluble components were removed by centrifugation.
さらに上記溶媒５００−で残渣を洗浄して卵黄蛋白質画
分を得た。さらに卵黄蛋白質画分をＲＯ膜で脱塩、濃縮
し、濃縮液を凍結乾燥して、卵黄蛋白質（ＥＹＰ−Ｎ）
を含む粉末を得た。収量は鶏卵２０個当り４２ｇであっ
た。Further, the residue was washed with the above solvent 500 to obtain an egg yolk protein fraction. Furthermore, the egg yolk protein fraction was desalted and concentrated using an RO membrane, and the concentrated solution was freeze-dried to produce egg yolk protein (EYP-N).
A powder containing was obtained. The yield was 42 g per 20 chicken eggs.
実施例２
卵黄蛋白トリプシン分解物（ＥＹＰ−Ｔ）の調製新鮮鶏
卵２０個を実施例１に記載した方法で脱脂し、卵黄蛋白
質画分を調製し、水２１を加えて溶解後、ＮａＯＨで、
ｐＨ７，０に調整したあとトリプシン２ｇを添加し、３
７°Ｃで３時間反応させて、卵黄蛋白トリプシン分解物
を生成せしめた。その後、８４°Ｃに５分間保持して酵
素を失活せしめ、ＲＯ膜で脱塩し、濃縮液を得た。濃縮
液を凍結乾燥し、卵黄蛋白トリプシン分解物（ＥＹＰ−
Ｔ）を含む粉末を得た。Example 2 Preparation of trypsin-digested egg yolk protein (EYP-T) 20 fresh chicken eggs were defatted by the method described in Example 1 to prepare an egg yolk protein fraction, dissolved by adding 21 parts of water, and then dissolved with NaOH.
After adjusting the pH to 7.0, add 2 g of trypsin and
The reaction was carried out at 7°C for 3 hours to generate trypsin-digested egg yolk protein. Thereafter, the enzyme was kept at 84°C for 5 minutes to inactivate it, and the mixture was desalted using an RO membrane to obtain a concentrated solution. The concentrate was freeze-dried and converted into egg yolk protein trypsin digested product (EYP-
A powder containing T) was obtained.
収量は鶏卵２０個当り４７ｇであった。The yield was 47 g per 20 chicken eggs.
実施例３
卵黄蛋白質（ＥＹＰ−Ｎ）および卵黄蛋白トリプシン分
解物（ＥＹＰ−Ｔ）の骨強化効果
（１）被験試料を添加したラット飼料組成試験に使用し
た飼料の組成を第１表及び第２表に示す。Example 3 Bone strengthening effect of egg yolk protein (EYP-N) and egg yolk protein tryptic digest (EYP-T) (1) Rat feed composition to which the test sample was added The composition of the feed used in the test is shown in Tables 1 and 2. Shown in the table.
第１表 飼料基本組成（ｇ／１００ｇ）蔗
［！４９
コーンスターチ １５
トウモロコシ油 ５
Ｄ−１，メチオニン ０．３
セルロース ５
ビ タ ミ ン １．２（コリンを含
む）
ＥＹＰ−Ｎ
その他 １．１３ １．１３ １．１３ １．
１３１．１３
蔗１！ ０．８３ ０．８３ ０．８３ ０．８３１
．５６
実施例１および２で得られたＥＹＰ−Ｎ及びＥＹＰ−Ｔ
を第２表に示すように飼料にそれぞれ別々に１％添加し
、カゼインで飼料中蛋白量が２０％になるよう調整した
。飼料中力ルシウム量は、すべての群で飼料１００ｇあ
たりのカルシウム量が３００■となるよう炭酸カルシウ
ムで調整した。またリン４００■、カリウム３５０■、
マグネシウム８０■、ナトリウム１００■になるように
調整した。Table 1 Basic feed composition (g/100g) Potato
[! 49 Cornstarch 15 Corn oil 5 D-1, methionine 0.3 Cellulose 5 Vitamins 1.2 (including choline) EYP-N Others 1.13 1.13 1.13 1.
131.13 Sweet potato 1! 0.83 0.83 0.83 0.831
．． 56 EYP-N and EYP-T obtained in Examples 1 and 2
were separately added to the feed at 1% as shown in Table 2, and the protein content in the feed was adjusted to 20% with casein. The amount of lucium in the feed was adjusted with calcium carbonate so that the amount of calcium per 100 g of feed was 300 μl in all groups. Also, phosphorus 400■, potassium 350■,
Adjustments were made so that the magnesium content was 80 ■ and the sodium content was 100 ■.
（２）使用動物及び骨粗■症モデル動物の作成動物は５
週齢のＳＤ系雌性ラットを用いた。骨粗鬆症モデルラッ
トは、１週間予備飼育した後に卵巣摘出手術を施し低カ
ルシウム食で１力月間飼育することにより作成した。■
試験群各７匹で試験を行った。(2) Animals used and animals used to create osteoporosis model animals are 5
Week-old SD female rats were used. Osteoporosis model rats were prepared by preliminarily rearing for one week, followed by ovariectomy, and then rearing on a low-calcium diet for one month. ■
The test was conducted with 7 animals in each test group.
（３）管弦化試験
骨粗鬆症モデルラットを上記被験飼料で１力月間飼育し
た後、大腿骨を摘出し管強度を破断特性測定装置で測定
した。(3) Tube formation test After the osteoporosis model rats were fed with the above-mentioned test feed for one month, the femurs were removed and the tube strength was measured using a fracture property measuring device.
（４）試験結果
試験結果を第１図及び第２図に示す。第１図に示したよ
うに骨破断力は、ＥＹＰ−Ｎ及びＥＹＰ−Ｔを加えない
対照群に比べ、卵黄蛋白（ＥＹＰ−Ｎ）を加えた群およ
び卵黄蛋白トリプシン分解物（ＥＹＰ−Ｔ）を加えた群
で顕著に高い値を示した。第２図に示した骨破断エネル
ギーも卵黄蛋白および卵黄蛍白トリプシン分解物を加え
ない対照群や低カルシウム群に比べ、加えた群で顕著に
高い値を示した。しかもジャムＣａＣ０１添加群よりも
高い値を示した。このことから、卵黄蛋白（ＥＹＰ−Ｎ
）および卵黄蛋白トリプシン分解物（ＥＹＰ−Ｔ）に管
弦化作用があることが分かった。(4) Test results The test results are shown in Figures 1 and 2. As shown in Figure 1, the bone breaking force was higher in the group to which egg yolk protein (EYP-N) was added and the group to which egg yolk protein tryptic degradation product (EYP-T) was added, compared to the control group to which EYP-N and EYP-T were not added. A significantly higher value was observed in the group in which . The bone fracture energy shown in FIG. 2 was also significantly higher in the group to which egg yolk protein and egg yolk fluorescent white tryptic digest were added than in the control group and the low calcium group. Moreover, it showed a higher value than the jam CaC01 addition group. From this, egg yolk protein (EYP-N
) and egg yolk protein tryptic digest (EYP-T) were found to have a tube-forming effect.
本発明の食品、飼料あるいは医薬について実施例をあげ
て具体的に示す。The food, feed, or medicine of the present invention will be specifically illustrated by giving examples.
実施例４ （ＥＹＰ−Ｎまたはｔ！ＹＰ−Ｔ入り飲料）
重量％
水 ７３．８
上記配合比によって通常の製造法にて果汁飲料を製造し
た。Example 4 (Beverage containing EYP-N or t!YP-T)
Weight % Water 73.8 A fruit juice drink was produced using the above-mentioned blending ratio using a conventional production method.
実施例５ （ＥＹＰ−ＮまたはＥＹＰ−Ｔ入りゼリー）
製造した。Example 5 (Jelly containing EYP-N or EYP-T)
Manufactured.
実施例６ （ＥＹＰ−ＮまたはＥＹＰ−Ｔ入り錠剤）上
記配合比によって通常の製造法にて錠剤を製造した。得
られた食品は、カルシウム及び蛋白補強の栄養剤として
１日５〜６錠あるいは骨粗鬆症の予防または治療に１日
６〜１０錠投与することができる。Example 6 (Tablet containing EYP-N or EYP-T) Tablets were manufactured using the above-mentioned compounding ratio and a conventional manufacturing method. The obtained food can be administered 5 to 6 tablets per day as a nutritional supplement for calcium and protein, or 6 to 10 tablets per day for prevention or treatment of osteoporosis.
実施例７〔イヌ飼育用飼料（ドッグフード）〕水
５８．３
ＥＹＰ−ＮまたはＥＹＰ−Ｔ
上記配合比によって通常の製造法にてゼリーを１）ビタ
ミン混合物
ビタミンＡ
ビタミンＤ３
ショ糖で２ｇ
２）ミネラル混合物
ａＣＯ３
ＫＨ，ＰＯ４
ＮａＨ２ＰＯ４
ｇＯ
ｎＣＯ３
１５００１［１
３００Ｉｕ
とした。Example 7 [Dog feed (dog food)] Water 58.3 EYP-N or EYP-T Make jelly using the usual manufacturing method according to the above mixing ratio 1) Vitamin mixture Vitamin A Vitamin D3 2g of sucrose 2) Minerals Mixture aCO3 KH, PO4 NaH2PO4 gO nCO3 15001 [1 300 Iu.
３．０ｇ ２．０ｇ １．５ｇ ０．５ｇ ４０．０■ の製造法にてイヌ飼育用飼料を製造した。3.0g 2.0g 1.5g 0.5g 40.0■ A feed for breeding dogs was manufactured using the manufacturing method described above.
主肌■四来
本発明の管弦化食品、飼料、医薬は骨を強化する作用が
あることから健康食品あるいは各種の骨関節疾患、特に
骨粗Ｎ症の予防あるいは治療に有用である。Main skin ■ Four aspects Since the orchestrated foods, feeds, and medicines of the present invention have a bone-strengthening effect, they are useful as health foods or in the prevention or treatment of various bone and joint diseases, especially osteoporosis.
第１図及び第２図は実施例３の管弦化試験の結果をそれ
ぞれ示す。FIGS. 1 and 2 show the results of the orchestration test of Example 3, respectively.
Claims (4)
りなる水可溶性画分を含有せしめてなる骨強化食品、飼
料または医薬。(1) A bone-strengthening food, feed, or medicine containing a water-soluble fraction consisting of egg yolk proteins and peptides obtained by defatting egg yolk.
水可溶性画分を蛋白分解酵素で酵素分解し、得られる分
子量４００００〜２０００の蛋白分解酵素分解物よりな
る水可溶性画分を含有せしめてなる骨強化食品、飼料ま
たは医薬。(2) Defatting the egg yolk, enzymatically decomposing the resulting water-soluble fraction of egg yolk proteins and peptides with a protease, and containing the resulting water-soluble fraction consisting of a proteolytic enzyme decomposition product with a molecular weight of 40,000 to 2,000. bone-strengthening food, feed or medicine.
は蛋白分解酵素分解物よりなる水可溶性画分をさらに脱
塩しこれを含有せしめてなる請求項（１）または（２）
記載の骨強化食品、飼料または医薬。(3) Claim (1) or (2) wherein the water-soluble fraction consisting of egg yolk protein and peptide or the water-soluble fraction consisting of a proteolytic enzyme decomposition product is further desalted and contained.
Bone-strengthening food, feed or medicine as described.
は、蛋白分解酵素分解物よりなる水可溶性画分を脱塩し
て卵黄由来のリンを含む塩を除き、これを適当なカルシ
ウム塩とともに含有せしめてなる請求項（１）〜（３）
のいずれかに記載の骨強化食品、飼料または医薬。(4) Desalting the water-soluble fraction consisting of egg yolk proteins and peptides or the water-soluble fraction consisting of proteolytic enzyme decomposition products to remove salts containing egg yolk-derived phosphorus, and containing this together with an appropriate calcium salt. Claims (1) to (3)
Bone-strengthening food, feed or medicine according to any of the above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2165085A JPH0453471A (en) | 1990-06-22 | 1990-06-22 | Bone-enriched food, feed and medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2165085A JPH0453471A (en) | 1990-06-22 | 1990-06-22 | Bone-enriched food, feed and medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0453471A true JPH0453471A (en) | 1992-02-21 |
Family
ID=15805596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2165085A Pending JPH0453471A (en) | 1990-06-22 | 1990-06-22 | Bone-enriched food, feed and medicine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0453471A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07143863A (en) * | 1993-11-24 | 1995-06-06 | Maguoole Sci Kk | Method for producing magnesium-reinforced food |
| JPH08208490A (en) * | 1994-09-26 | 1996-08-13 | American Cyanamid Co | Improved calcium dietary supplement composition |
| JP2001294523A (en) * | 2000-04-12 | 2001-10-23 | Nisshin Seifun Group Inc | Composition for vitamin k deficiency |
| JP2005047844A (en) * | 2003-07-28 | 2005-02-24 | Hiroshi Yamazaki | Decomposition product of organism-derived polymer material, food, cosmetic and medicine containing the same and method for producing them |
| JPWO2006075558A1 (en) * | 2005-01-11 | 2008-08-07 | 株式会社ファーマフーズ | Egg-derived bone strengthening composition |
| JP2010148455A (en) * | 2008-12-25 | 2010-07-08 | Uha Mikakuto Co Ltd | Hard candy |
| JP2011211979A (en) * | 2010-03-31 | 2011-10-27 | Pharma Foods International Co Ltd | Peptide having osteoblast proliferation promotion activity and use thereof |
| WO2015129726A1 (en) * | 2014-02-25 | 2015-09-03 | 株式会社ファーマフーズ | Peptide having osteoblast proliferation-promoting activity and use thereof |
| JP2016531951A (en) * | 2013-10-04 | 2016-10-13 | イノウェイ・カンパニー・リミテッド | Animal protein hydrolyzate, production method thereof and use thereof |
| WO2018003817A1 (en) * | 2016-06-27 | 2018-01-04 | 株式会社ファーマフーズ | Preventative and/or therapeutic agent for osteogenesis imperfecta and the like |
-
1990
- 1990-06-22 JP JP2165085A patent/JPH0453471A/en active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07143863A (en) * | 1993-11-24 | 1995-06-06 | Maguoole Sci Kk | Method for producing magnesium-reinforced food |
| JPH08208490A (en) * | 1994-09-26 | 1996-08-13 | American Cyanamid Co | Improved calcium dietary supplement composition |
| JP2001294523A (en) * | 2000-04-12 | 2001-10-23 | Nisshin Seifun Group Inc | Composition for vitamin k deficiency |
| JP2005047844A (en) * | 2003-07-28 | 2005-02-24 | Hiroshi Yamazaki | Decomposition product of organism-derived polymer material, food, cosmetic and medicine containing the same and method for producing them |
| JP5213332B2 (en) * | 2005-01-11 | 2013-06-19 | 株式会社ファーマフーズ | Egg-derived bone strengthening composition |
| JPWO2006075558A1 (en) * | 2005-01-11 | 2008-08-07 | 株式会社ファーマフーズ | Egg-derived bone strengthening composition |
| KR101156703B1 (en) * | 2005-01-11 | 2012-06-14 | 가부시키 가이샤 파마푸즈 | Egg-derived bone-strengthening composition |
| JP2010148455A (en) * | 2008-12-25 | 2010-07-08 | Uha Mikakuto Co Ltd | Hard candy |
| JP2011211979A (en) * | 2010-03-31 | 2011-10-27 | Pharma Foods International Co Ltd | Peptide having osteoblast proliferation promotion activity and use thereof |
| JP2016531951A (en) * | 2013-10-04 | 2016-10-13 | イノウェイ・カンパニー・リミテッド | Animal protein hydrolyzate, production method thereof and use thereof |
| WO2015129726A1 (en) * | 2014-02-25 | 2015-09-03 | 株式会社ファーマフーズ | Peptide having osteoblast proliferation-promoting activity and use thereof |
| JPWO2015129726A1 (en) * | 2014-02-25 | 2017-03-30 | 株式会社ファーマフーズ | Peptide having osteoblast proliferation promoting activity and use thereof |
| US10538564B2 (en) | 2014-02-25 | 2020-01-21 | Pharma Foods International Co., Ltd. | Peptides having osteoblast growth-promoting activity and use thereof |
| WO2018003817A1 (en) * | 2016-06-27 | 2018-01-04 | 株式会社ファーマフーズ | Preventative and/or therapeutic agent for osteogenesis imperfecta and the like |
| US11241475B2 (en) | 2016-06-27 | 2022-02-08 | Pharma Foods International Co., Ltd. | Preventive and/or therapeutic agent for osteogenesis imperfecta and other diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101674839A (en) | Process for producing osteocalcin-containing extract | |
| US20020137688A1 (en) | Kolla2-desiccated avian sternal cartilage powder | |
| JP5465834B2 (en) | Liver function protectant | |
| JP3160862B2 (en) | Bone-fortified foods, feeds and pharmaceuticals | |
| KR101361379B1 (en) | Nutrient composition | |
| JP2947484B2 (en) | Bone-fortified food, feed or osteoarthritis prophylactic or therapeutic drug | |
| JP4596513B2 (en) | Nutritional composition | |
| JPH0453471A (en) | Bone-enriched food, feed and medicine | |
| NZ512182A (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
| CN101179953B (en) | Food composition for stimulating growth, comprising fraction isolated from mammalian colostrum or milk whey | |
| JP5213332B2 (en) | Egg-derived bone strengthening composition | |
| CN1330517A (en) | Food-induced antisecretory proteins in egg yolk | |
| JP3092874B2 (en) | Whey-derived osteoblast-proliferating and bone-enhancing fraction and bone-enhanced food, feed, and pharmaceuticals containing the fraction | |
| KR20100100845A (en) | Food material for inhibiting the formation of osteoclast | |
| CA2704144C (en) | Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast | |
| KR101441728B1 (en) | Food material for inhibiting bone resorption | |
| JP7025112B2 (en) | BDNF production promoter | |
| JPH07215851A (en) | Antiallergic agent and its production | |
| RU2274003C2 (en) | Method for complex processing agricultural animals blood for preparing hemoglobin-base biologically active substance with anti-anemic properties, biologically active substance with anti-anemic properties (variants) and product comprising thereof (variants) | |
| JP2567231B2 (en) | Dietary supplement for enhancing endurance | |
| JP2021010374A (en) | Bdnf production promoting agent | |
| JP2005021087A (en) | Egg-derived bone strengthening composition | |
| Merkle et al. | Chicken Eggs and Human Health | |
| Merkle et al. | 16 Chicken Eggs and | |
| JPH09121812A (en) | Calcium absorption promoter and food / drink, feed or drug containing the same |